CurrentCommunity-CarePolicy N/A

Rystiggo (rozanolixizumab) — Medical Benefit Medication Utilization Policy

Medically necessary criteria, authorization limits, and coding for use of rozanolixizumab (Rystiggo) under the medical benefit for treatment of generalized myasthenia gravis in covered members.

Policy Summary

PayerCommunity-Care

PolicyRystiggo (rozanolixizumab) — Medical Benefit Medication Utilization Policy

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateSep 1, 2024

Key ActionObtain prior authorization and document neurologist involvement, required serology, MG-ADL score ≥3 with ≥3 non-ocular points, and prior therapy trials or rationale for contraindication/intolerance.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

MG-ADL ≥ 3minimum symptom score required

MGFA II-IVdisease severity classes eligible

36 mLmax quantity per 63 days

1 yearauthorization period

J9333HCPCS code

Coverage Criteria for Rystiggo (rozanolixizumab)

Initial Therapy

Covered when ALL of the following are met for initial approval:

Initial Approval Criteria

Prescriber: Prescribed by, or in consultation with, a neurologist
[[chunk 0]]
Diagnosis of generalized myasthenia gravis
[[chunk 0]]
Serology: One of: positive serologic test for anti-acetylcholine receptor (AChR) antibodies OR positive serologic test for anti-muscle-specific tyrosine kinase (MuSK) antibodies
[[chunk 0]]

Policy Summary

PayerCommunity-Care

PolicyRystiggo (rozanolixizumab) — Medical Benefit Medication Utilization Policy

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateSep 1, 2024

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Continuation Therapy

Covered when ALL of the following are met for continuation:

Continuation Approval Criteria

Diagnosis of generalized myasthenia gravis
[[chunk 0]]
Clinical response: Attestation of a positive clinical response to therapy
[[chunk 0]]
Concomitant biologics: Will not be used in combination with other biologic therapies for myasthenia gravis
[[chunk 0]]

Operational note: Continuation requests should include documentation of clinical response; absence of documented response may result in denial.

[[chunk 0]]

Prior Authorization and Documentation Requirements

Prior Authorization

Prior Authorization Required

Prior authorization is required for rozanolixizumab (Rystiggo) and will be granted only when all initial criteria are met. If approved, authorization is for up to 1 year and quantities are limited to 36 mL (5,040 mg) per 63 days.

Prior authorization required before dispensing
Authorized quantity: up to 36 mL (5,040 mg) per 63 days
Authorization period: up to 1 year (subject to benefit changes)

Step Therapy

Required Prior Therapeutic Trials

Prior to approval, documentation must show trials of the following or a documented contraindication/intolerance: an acetylcholinesterase inhibitor, and either an oral corticosteroid or an oral non‑steroidal immunosuppressant (or documentation that both are contraindicated or not tolerated).

Trial of an acetylcholinesterase inhibitor (ineffective, contraindicated, or not tolerated)
Trial of either an oral corticosteroid or an oral non‑steroidal immunosuppressant (ineffective, contraindicated, or not tolerated)

Documentation Required

Required Documentation

Provide clear clinical documentation with the prior authorization request: patient is under care of or consulted with a neurologist; diagnosis of generalized myasthenia gravis; MGFA clinical class documented as II–IV; baseline MG‑ADL total score ≥ 3 with ≥ 3 points from non‑ocular symptoms; results of serologic testing for AChR or MuSK antibodies; description of prior therapies and why they were ineffective or not tolerated; and that therapy will not be used in combination with other biologic MG therapies.

Prescriber is a neurologist or consultation with a neurologist is documented
Diagnosis: generalized myasthenia gravis
MGFA class documented: II–IV
Baseline MG‑ADL total score ≥ 3 with ≥ 3 non‑ocular points
Serologic test result: positive AChR or MuSK antibody (or documentation)
Documentation of prior trials and reasons for failure/intolerance/contraindication (acetylcholinesterase inhibitor; corticosteroid or steroid‑sparing agent)
Statement that rozanolixizumab will not be used with other biologic MG therapies

Denial Risk

Denial Triggers

Claims or PA requests may be denied if required criteria or documentation are missing or not met. Common denial reasons include: diagnosis not generalized myasthenia gravis; MGFA class outside II–IV; MG‑ADL score below threshold or lacking non‑ocular points; absence of documented serologic testing or positive antibody status; no documentation of prior trials (or documented contraindication/intolerance) of required agents; prescriber not a neurologist or lacking neurologist consultation; or intent to use in combination with other biologic MG therapies.

Diagnosis not documented as generalized myasthenia gravis
MGFA class not II–IV
MG‑ADL total score < 3 or < 3 non‑ocular points
No positive AChR or MuSK serology documented (or adequate alternative documentation)
Missing documentation of prior trials or contraindications/intolerances (acetylcholinesterase inhibitor; corticosteroid or immunosuppressant)
No neurologist involvement or consultation documented
Request indicates combination use with other biologic MG therapies

Background

Rozanolixizumab (Rystiggo) is indicated for the treatment of generalized myasthenia gravis. This policy defines the medical necessity criteria and limits for the medical‑benefit use of rozanolixizumab, including requirements for neurologist involvement, documented generalized MG diagnosis, qualifying serology (anti‑AChR or anti‑MuSK), disease severity (MGFA Class II–IV), a functional impairment threshold of MG‑ADL ≥ 3 with ≥ 3 non‑ocular points, required prior trials of standard therapies (acetylcholinesterase inhibitor and an oral corticosteroid or oral non‑steroidal immunosuppressant unless contraindicated/intolerant), exclusions for concomitant biologic use, quantity limits, and prior authorization requirements.

OpenPayer

Rystiggo (rozanolixizumab) — Medical Benefit Medication Utilization Policy

Coverage Criteria for Rystiggo (rozanolixizumab)

Coding and Quantity Limits

Prior Authorization and Documentation Requirements

Clinical Definitions and Thresholds

Background